en · de · es · fr · pt
cjc-1295-notes.peptides6908.com › Wiki › Cjc-1295 Structure And Mechanism — Research Overview

Cjc-1295 Structure And Mechanism — Research Overview

By Editorial Desk · published 2025-09-30 · last reviewed 2025-10-19 · Wiki

This is a working overview of albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-10-19. Anything still debated is marked as such rather than presented as settled.

CJC-1295 Structure And Mechanism

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

Mechanism and Pharmacokinetics

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Cjc-1295 at a glance

PropertyValueNotes
Physical formLyophilized white powderSupplied as a freeze-dried solid for research use
Molecular weightApproximately 3,647 Da (DAC form)Lower for the variant lacking the albumin-binding moiety
SolubilitySoluble in water and aqueous bufferTypically dissolved in sterile or bacteriostatic water
Typical storage temperature−20 °C or belowDry powder, desiccated and protected from light
Common analytical methodReversed-phase HPLC with mass spectrometryUsed for purity estimation and identity confirmation

Receptor Action and Pharmacokinetics

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Related pages on this site

Molecular Background and Naming

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

Structure And Receptor Pharmacology

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Further detail

Human chorionic gonadotropin is a glycoprotein composed of 237 amino acids with a molecular mass of 36.7 kDa, approximately 14.5kDa αhCG and 22.2kDa βhCG. It is heterodimeric, with an α (alpha) subunit identical to that of luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and a β (beta) subunit that is unique to hCG. The α (alpha) subunit is 92 amino acids long. The β-subunit of hCG gonadotropin (beta-hCG) contains 145 amino acids, encoded by six highly homologous genes that are arranged in tandem and inverted pairs on chromosome 19q13.3 - CGB (1, 2, 3, 5, 7, 8). It is known that CGB7 has a sequence slightly different from that of the others. The two subunits create a small hydrophobic core surrounded by a high surface area-to-volume ratio: 2.8 times that of a sphere. The vast majority of the outer amino acids are hydrophilic. beta-hCG is mostly similar to beta-LH, with the exception of a Carboxy Terminus Peptide (beta-CTP) containing four glycosylated serine residues that is responsible for hCG's longer half-life.

For homozygosity, the incidence is approximately 1:2,000-4,000, whereas the incidence for heterozygosity increases to up to 1:500. The variant EaEa genotype, homozygous absent, is approximately 1:3200. The gene for the dibucaine-resistant atypical cholinesterase appears to be widely distributed. Among Caucasians, males are affected almost twice as often as females. The frequency for heterozygosity is low among black people, Japanese and non-Japanese Asians, South Americans, Australian Aboriginal peoples, and Arctic Inuit (in general). However, there are a few Inuit populations (e.g., Alaskan Inuit) with an unusually high gene frequency for BChE deficiency. A relatively high frequency also was reported among Jews from Iran and Iraq, Caucasians from North America, Great Britain, Portugal, Yugoslavia, and Greece.

=== Organothorium compounds === Most of the work on organothorium compounds has focused on the cyclopentadienyl complexes and cyclooctatetraenyls. Like many of the early and middle actinides (up to americium, and also expected for curium), thorium forms a cyclooctatetraenide complex: the yellow Th(C8H8)2, thorocene. It is isotypic with the better-known analogous uranium compound uranocene. It can be prepared by reacting K2C8H8 with thorium tetrachloride in tetrahydrofuran (THF) at the temperature of dry ice, or by reacting thorium tetrafluoride with MgC8H8. It is unstable in air and decomposes in water or at 190 °C. Half sandwich compounds are also known, such as (η8-C8H8)ThCl2(THF)2, which has a piano-stool structure and is made by reacting thorocene with thorium tetrachloride in tetrahydrofuran. The simplest of the cyclopentadienyls are Th(C5H5)3 and Th(C5H5)4: many derivatives are known. The former (which has two forms, one purple and one green) is a rare example of thorium in the formal +3 oxidation state; a formal +2 oxidation state occurs in a derivative. The chloride derivative [Th(C5H5)3Cl] is prepared by heating thorium tetrachloride with limiting KC5H5 used (other univalent metal cyclopentadienyls can also be used). The alkyl and aryl derivatives are prepared from the chloride derivative and have been used to study the nature of the Th–C sigma bond. Other organothorium compounds are not well-studied. Tetraallylthorium, Th(CH2CH=CH2)4, is known, but its structures has not been determined.

The partisan section took care of the armed defense of the territory, women assisted men with provisions, and party cadres had to keep in touch with the party federation. The revolutionaries established a “People's Tribunal,” which was based in the town square and had the power to try “enemies of the people". An internment camp held many agrarians and notables. The revolutionary experience worried both conservatives and communist leaders, who pressed Cavallaro to calm tempers and end the revolution. The mayor became spokesman for the rebels and convinced most of them to return home and lay down their arms. Diehards refused and went into hiding. Finally, on March 9, the prefect of Reggio Calabria sent departments of carabinieri and police to Caulonia. They arrested 365 men, who were referred to the Locri court for constitution of an armed gang, murder, violence to private individuals and usurpation of public office. On April 15, Cavallaro resigned as mayor. British historian Jonathan Dunnage reported an "institutional continuity" of the civil servants who survived these regime changes Civil servants were not purged either after 1922 or 1943. The "institutional continuity" of the bureaucracy of Calabria were committed to preserving the social structure. On 2 June 1946 Calabria, like the rest of the Mezzogiorno, voted solidly to retain the monarchy. The traditional political system in Calabria continued after 1945. During the war, the already low living standards of Calabria declined further and the region was notorious as one of Italy's most violent areas.

Sources: en.wikipedia.org

Background from the literature

=== Main group elements and lanthanides === The mechanisms of main group compounds of groups 13–18 are usually discussed in the context of organic chemistry (organic compounds are main group compounds, after all). Elements heavier than C, N, O, and F often form compounds with more electrons than predicted by the octet rule, as explained in the article on hypervalent molecules. The mechanisms of their reactions differ from organic compounds for this reason. Elements lighter than carbon (B, Be, Li) as well as Al and Mg often form electron-deficient structures that are electronically akin to carbocations. Such electron-deficient species tend to react via associative pathways. The chemistry of the lanthanides mirrors many aspects of chemistry seen for aluminium.

=== Industrial discharge === Industrial discharge is when waste products are released into the environment from manufacturing and chemical processing facilities. This waste can include a wide variety of CEC like heavy metals, solvents, and various organic compounds that are not regularly detected for or removed by standard treatment processes. These contaminants can accumulate in sediments and biota, posing risks to aquatic life and human health. The complexity and diversity of industrial discharge requires advanced treatment technologies and stricter regulatory frameworks to prevent CEC from contaminating the environment. Advanced oxidation processes and membrane technologies have been researched and shown to reduce CEC from industrial discharge, however there is an excessive cost to retrofit existing treatment facilities with this technology.

In human anatomy, the penis (; pl.: penises or penes; from the Latin pēnis, initially 'tail') is an external sex organ (intromittent organ) through which males ejaculate and urinate. Together with the testes and surrounding structures, the penis functions as part of the male reproductive system. The main parts of the penis are the root, body, the epithelium, including the shaft skin, and the foreskin covering the glans. The body of the penis is made up of three columns of tissue: two corpora cavernosa on the dorsal side and corpus spongiosum between them on the ventral side. The urethra passes through the prostate gland, where it is joined by the ejaculatory ducts, and then passes through the corpus spongiosum. The external opening of the urethra at the tip of the glans is the urinary meatus. An erection is the stiffening expansion and orthogonal reorientation of the penis, which occurs during sexual arousal. Erections can occur in non-sexual situations; spontaneous non-sexual erections frequently occur during adolescence and sleep. In its flaccid state, the penis is smaller, gives to pressure, and the glans is covered by the foreskin. In its fully erect state, the shaft becomes rigid and the glans becomes engorged but not rigid. An erect penis may be straight or curved and may point at an upward angle, a downward angle, or straight ahead. As of 2015, the average erect human penis is 13.12 cm (5.17 in) long and has a circumference of 11.66 cm (4.59 in). Neither age nor size of the flaccid penis accurately predicts erectile length.

In 1993, the first success of an mRNA vaccine was reported in mice, by using liposome-encapsulated IVT mRNA which is encoding the nucleoprotein of influenza that induced virus-specific T cells. Then, IVT mRNA was formulated with synthetic lipid nanoparticles and it induced protective antibody responses against the respiratory syncytial virus(RSV) and influenza virus in mice. There are a few different types of IVT mRNA-based vaccine development for infectious diseases. One of the successful types is using self-amplifying IVT mRNA that has sequences of positive-stranded RNA viruses. It was originally developed for a flavivirus and it was workable with intradermal injection. One of the other ways is injecting a two-component vaccine which is containing an mRNA adjuvant and naked IVT mRNA encoding influenza hemagglutinin antigen only or in combination with neuraminidase encoding IVT mRNA. For example, for the HIV treatment, vaccines are using DCs transfected with IVT mRNA that is encoding HIV proteins. There are a few phase I and II clinical trials using IVT mRNA encoding combinations and it shows that antigen-specific CD8+ and CD4+ T cell responses can be induced. However, no antiviral effects have been observed in the clinical trial. One of the other mRNA vaccines is for COVID-19. The Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) outbreaks in December 2019 and spread all over the world, causing a pandemic of respiratory illness designated coronavirus disease 2019 (COVID-19).

=== Detection === This tag can also be used in detection of the protein via anti-biotin antibodies or avidin/streptavidin-tagged detection strategies such as enzyme reporters (e.g., horseradish peroxidase, alkaline phosphatase) or fluorescent probes. This can be useful in localization by fluorescent or electron microscopy, ELISA assays, ELISPOT assays, western blots and other immunoanalytical methods. Detection with monovalent streptavidin can avoid clustering or aggregation of the biotinylated target.

Sources: en.wikipedia.org

Frequently asked questions

How does CJC-1295 differ from modified GRF(1-29)?

The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.

Is CJC-1295 an approved medicine?

It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.

What is known about its half-life?

Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.

How long does the albumin-binding form remain active?

Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.

Network